Prostate Cancer

Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.

A prostate cancer expert explains the potential advantages of sabizabulin, a new treatment for metastatic castration-resistant prostate cancer currently in a phase III clinical trial.

The patient's treatment included prostate-specific membrane antigen (PSMA)–PET imaging.

“This study is a great example of research questions coming directly out of clinical practice. It’s so important to listen to patients, understand their experiences and use research findings to guide clinical practice about how best to talk with and advise patients," says Katherine Sterba, PhD.

“I think this is a tremendous opportunity for the Black community and for Black men. I hope my story can encourage other men to get prostate cancer screenings and possibly save a life. Every life is important," says Larry J. Ferguson, DMD.

Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.

"It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer," writes Badar M. Mian, MD.

Robert Dreicer, MD, provides an overview of the first-line therapy options available in metastatic castration-resistant prostate cancer and the recent advances in detection, diagnosis, and treatment.

On this episode of Cleveland Clinic’s Cancer Advances podcast, Eric Klein, MD, discusses the novel IsoPSA test and how it differs from conventional PSA testing.

Results also showed that Black men were 29% more likely to be diagnosed with prostate cancer using a diagnostic prostate biopsy vs White men.

The study is enrolling patients with metastatic castration-resistant prostate cancer who have not received second-generation anti-androgen therapies.

“It's really become the epicenter of all the surgeries that we do in urology,” says Jennifer Linehan, MD.

“Our team showed that treating a group of approximately 10 to 15 men with hormone therapy or extended adjuvant hormone therapy, for at least 18 months, prevented one man from developing metastatic disease 10 years after treatment," says Daniel E. Spratt, MD.

The combination of abiraterone acetate, prednisolone, and androgen deprivation therapy (ADT) with or without enzalutamide delivers a strong metastasis-free survival boost versus treatment with ADT alone in patients with high-risk non-metastatic prostate cancer.

These research and technology breakthroughs are designed to improve outcomes and the patient experience.

This real-world cohort study corroborates prior research showing a greater clinical benefit for abiraterone acetate in African American versus White patients with metastatic castration-resistant prostate cancer.

Researchers uncover how diet, lifestyle modifications may lower risk of lethal disease.

“It doesn't need to be surgery or radiation. Setting that stage, really focusing on those conversations, using the appropriate tools that we've grasped from behavioral psychologists that are being used by negotiation specialists, are critical in medicine,” says Behfar Ehdaie, MD, MPH.

The improved response to radiotherapy was observed despite Black men having more aggressive disease at enrollment.

“We’ll be able to take a drop of blood in a community setting such as a barbershop and be able to deliver results in 10 to 15 minutes right there,” says investigator Saurabh Mehta, ScD.

“I think in specialized cases, especially for patients [who] need focal therapy or want focal therapy, or [for whom] you're really trying to minimize any nerve damage or urethral damage…these are excellent therapies,” says Jennifer Linehan, MD.

"There are many aspects of urology that get equal attention. Cancer will always attract attention and dollars, but it’s trickier to solve," says 1 urologist.

William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.

"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.

“You can be 2 to 3 mm from another organ and still safely treat the tissue that you want to,” says Jennifer Linehan, MD.